Organon & Co. $OGN Shares Purchased by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA significantly increased its stake in Organon & Co. by 32,333.3% during Q1, now holding 43,785 shares valued at approximately $602,000.
• Organon recently posted an EPS of $1.00 for the quarter, exceeding analyst expectations of $0.94 and showing a 11.15% net margin.
• The company will pay a quarterly dividend of $0.02 on September 11th, which equates to an annualized yield of 0.8%.

Banque Transatlantique SA grew its position in Organon & Co. (NYSE:OGN - Free Report) by 32,333.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,785 shares of the company's stock after buying an additional 43,650 shares during the quarter. Banque Transatlantique SA's holdings in Organon & Co. were worth $602,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Hsbc Holdings PLC lifted its stake in Organon & Co. by 13.9% during the 4th quarter. Hsbc Holdings PLC now owns 13,922 shares of the company's stock worth $208,000 after acquiring an additional 1,703 shares in the last quarter. NBC Securities Inc. lifted its stake in Organon & Co. by 111,262.5% during the 1st quarter. NBC Securities Inc. now owns 8,909 shares of the company's stock worth $132,000 after acquiring an additional 8,901 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in Organon & Co. by 42.2% during the 1st quarter. Sequoia Financial Advisors LLC now owns 19,392 shares of the company's stock worth $289,000 after acquiring an additional 5,758 shares in the last quarter. M&T Bank Corp lifted its stake in Organon & Co. by 3.4% during the 1st quarter. M&T Bank Corp now owns 55,990 shares of the company's stock worth $833,000 after acquiring an additional 1,854 shares in the last quarter. Finally, Cetera Investment Advisers lifted its stake in Organon & Co. by 62.7% during the 4th quarter. Cetera Investment Advisers now owns 76,005 shares of the company's stock worth $1,134,000 after acquiring an additional 29,287 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on OGN shares. Piper Sandler lowered their target price on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. BNP Paribas raised Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Organon & Co. currently has a consensus rating of "Moderate Buy" and an average price target of $17.33.

Organon & Co. Stock Up 0.9%

Shares of OGN traded up $0.10 during mid-day trading on Monday, reaching $10.48. The company's stock had a trading volume of 3,867,017 shares, compared to its average volume of 4,449,415. Organon & Co. has a 12-month low of $8.01 and a 12-month high of $21.06. The stock has a market cap of $2.72 billion, a PE ratio of 3.89, a price-to-earnings-growth ratio of 0.95 and a beta of 0.60. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13. The company's 50 day moving average is $9.59 and its 200 day moving average is $10.99.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, beating analysts' consensus estimates of $0.94 by $0.06. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.55 billion. During the same quarter in the prior year, the business posted $1.12 EPS. The business's revenue for the quarter was down .8% on a year-over-year basis. Organon & Co. has set its FY 2025 guidance at EPS. Equities analysts anticipate that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 11th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Organon & Co.'s dividend payout ratio is 2.97%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.